Clinical Trial Detail

NCT ID NCT02420821
Title A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

Therapies

Bevacizumab

Sunitinib

Atezolizumab

Age Groups: adult

No variant requirements are available.